About the Company
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (precision medicine), assess a patient's risk of disease progression and disease recurrence (precision medicine), and measure disease activity.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MYGN News
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
Myriad Genetics MYGN is well poised for growth in the coming quarters, backed by strong improvement in testing volume across all its businesses. Strong solvency is an added advantage. Yet, foreign ...
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of ...
CDC Said mRNA Jabs Have Caused a '14,000% Increase in Turbo Cancer'?
Adl-Tabatabai, Sean. "CDC: mRNA Jabs Have Caused 14,000% Increase in Turbo Cancer." The People's Voice, 15 Apr. 2024, ...
Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
Of those diagnosed with anxiety and/or depression, half (50%) said they have lost years of their lifetime because of poor ...
Millions of Americans have lost years of time to poor mental health
People who have lost time due to depressive episodes often feel a sense of loss, which further complicates their mental ...
Myriad’s test reduces gene-drug interactions, hospitalizations nearly 40%
Finding an effective medication for patients with major depressive disorder is notoriously difficult, with 70% of patients failing to respond to the first drug prescribed and 30% not responding to the ...
Global Theranostics Market Size To Worth USD 3.3 Billion By 2033 | CAGR Of 5.68%
The Global Theranostics Market Size was Valued at USD 1.9 Billion in 2023 and the Worldwide Theranostics Market Size is Expected to Reach USD 3.3 Bil ...
Russian TV Described Marjorie Taylor Greene as a 'Demonstrably Heterosexual' Beauty?
"She is a blonde who wears white coats with a fur collar," a pundit allegedly said. "She’s demonstrably heterosexual." ...
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Using AI to improve diagnosis of rare genetic disorders
Diagnosing rare Mendelian disorders is a labor-intensive task, even for experienced geneticists. Investigators at Baylor ...
Colorado woman recalls challenge after receiving second kidney transplant: "My first transplant was when I was 17, my dad gave me that"
Heidi Hughes is one of the lucky ones, who was able to find a donor for a kidney donation. She's on her second kidney, ...
Loading the latest forecasts...